AGL 40.18 Increased By ▲ 0.18 (0.45%)
AIRLINK 127.48 Increased By ▲ 0.44 (0.35%)
BOP 6.60 Decreased By ▼ -0.07 (-1.05%)
CNERGY 4.49 Decreased By ▼ -0.02 (-0.44%)
DCL 8.53 Decreased By ▼ -0.02 (-0.23%)
DFML 41.91 Increased By ▲ 0.47 (1.13%)
DGKC 87.65 Increased By ▲ 0.80 (0.92%)
FCCL 32.69 Increased By ▲ 0.41 (1.27%)
FFBL 65.21 Increased By ▲ 0.41 (0.63%)
FFL 10.30 Increased By ▲ 0.05 (0.49%)
HUBC 109.55 Decreased By ▼ -0.02 (-0.02%)
HUMNL 14.65 Decreased By ▼ -0.03 (-0.2%)
KEL 5.12 Increased By ▲ 0.07 (1.39%)
KOSM 7.52 Increased By ▲ 0.06 (0.8%)
MLCF 41.70 Increased By ▲ 0.32 (0.77%)
NBP 59.70 Decreased By ▼ -0.71 (-1.18%)
OGDC 194.00 Increased By ▲ 3.90 (2.05%)
PAEL 28.25 Increased By ▲ 0.42 (1.51%)
PIBTL 7.80 Decreased By ▼ -0.03 (-0.38%)
PPL 151.99 Increased By ▲ 1.93 (1.29%)
PRL 26.56 Decreased By ▼ -0.32 (-1.19%)
PTC 16.18 Increased By ▲ 0.11 (0.68%)
SEARL 84.67 Decreased By ▼ -1.33 (-1.55%)
TELE 7.70 Decreased By ▼ -0.01 (-0.13%)
TOMCL 35.39 Decreased By ▼ -0.02 (-0.06%)
TPLP 8.13 Increased By ▲ 0.01 (0.12%)
TREET 16.09 Decreased By ▼ -0.32 (-1.95%)
TRG 52.70 Decreased By ▼ -0.59 (-1.11%)
UNITY 26.31 Increased By ▲ 0.15 (0.57%)
WTL 1.26 No Change ▼ 0.00 (0%)
BR100 9,957 Increased By 73.1 (0.74%)
BR30 30,925 Increased By 325.2 (1.06%)
KSE100 93,782 Increased By 426.8 (0.46%)
KSE30 29,055 Increased By 123.7 (0.43%)
World

Japan orders 150 million doses of Novavax Covid vaccine

  • The cost of the deal was not announced, and it is contingent on the vaccine being approved in Japan
Published September 7, 2021

TOKYO: Japan has agreed to buy 150 million doses of Novavax's coronavirus vaccine, with Japanese firm Takeda expecting to manufacture the formula for distribution early next year, the drugmaker said Tuesday.

The cost of the deal was not announced, and it is contingent on the vaccine being approved in Japan. Takeda will be in charge of carrying out local clinical trials.

So far, Japan has approved the Pfizer/BioNTech, Moderna and AstraZeneca jabs, though the latter is being administered in a limited fashion.

Unlike the mRNA products from BioNTech/Pfizer, Moderna and Curevac, Novavax's two-jab vaccine relies on a more traditional technique, using proteins to carry fragments of the coronavirus rendered harmless to produce an immune reaction.

This means it does not have to be stored in ultra-low temperatures, potentially giving it a logistical edge.

US firm Novavax says its vaccine has 90 percent efficacy against Covid-19, based on a North American study. US and EU regulators have not yet given their evaluation of the jab's efficacy.

Last month, the European Commission announced it had signed a preliminary deal to buy up to 200 million doses of the vaccine, also contingent on its approval by the EU regulator.

After a comparatively slow start, Japan's vaccination programme has picked up speed, with around 48 percent of the population now fully vaccinated.

Comments

Comments are closed.